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1146Invasive coronary angiography
(ICA) is the established clinical
standard for detecting coronary
artery disease (CAD). The cor-
relation between angiographic
and physiological stenosis severity,
however, is poor (1,2). Because
coronary physiology trumps anat-
omy for clinical outcome (3,4),
current guidelines for the man-
agement of stable CAD recom-See page 1156mend documenting ischemia by
using a noninvasive functional
test (e.g., single photon emis-
sion computed tomography, stress
echocardiography, cardiac mag-
netic resonance [cMR]) before
considering ICA or coronary
revascularization (4,5). Shortcom-
ings of current noninvasive diag-
nostic strategies in CAD, however,
are apparent from the frequentlyinaccurate selection of patients for ICA (6). Fractional ﬂow
reserve (FFR), which assesses the ratio of ﬂow across a
stenosis to putative ﬂow in the absence of a stenosis, has
been shown to be a powerful tool for detecting lesion-
speciﬁc myocardial ischemia. Several randomized trials
have shown that an FFR threshold of 0.80 distinguishes
patients and coronary lesions that will beneﬁt from coronary
revascularization (7) from those that will not (8). Conse-
quently, FFR is the accepted reference standard for assessing
the functional signiﬁcance of CAD in a lesion-speciﬁc
manner (4). Noninvasive anatomic assessment by coronary
computed tomography angiography (CTA) is being
increasingly used as an accurate tool for detecting or
excluding CAD (9–12). Although the absence of coronary
stenoses according to coronary CTA is associated with an
excellent prognosis and obviates the need for any further
diagnostic evaluation (11), the correlation of stenoses
detected by using coronary CTA to downstream myocardial
ischemia is poor (13). Recently, a method using computa-
tional ﬂuid dynamics to calculate coronary blood ﬂow,
pressure, and FFR based on routinely acquired coronarygium; #Department of Cardiology, Harrington
sity Hospitals, Cleveland, Ohio; **Department
Hospital, Erlangen, Germany; yyDepartment
abeth-Krankenhaus Essen, Essen, Germany;
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niversity of Ulsan College of Medicine, Asan
Funding for the study was provided by Heart-
esearch grants from Abbott Vascular, Boston
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rves as a consultant for St. Jude Medical,CTA datasets at rest (FFRCT) has been described (14–16).
FFRCT combines anatomic and functional information to
enable appropriate therapeutic decision making. This
method has tremendous potential because noninvasive
determination of FFR may be a unique, useful test to
differentiate individuals who will or will not beneﬁt from
revascularization, and thus FFRCT has the potential of being
a reliable gatekeeper to the pathway of ICA.
The aim of the present study was to assess the diagnostic
performance of FFRCT by using invasive FFR as the refer-
ence standard. Compared with previous studies (15,16), a
substantially reﬁned version of the FFRCT technology was
used, and the emphasis on coronary CTA acquisition quality
was strengthened.Methods
Study design. The rationale and design of the NXT
(Analysis of Coronary Blood Flow Using CT Angiography:
Next Steps) study have been described previously (17). The
study was designed to characterize FFRCT diagnostic ac-
curacy in patients suspected of having CAD by using
invasive FFR as the reference standard, and it reﬂects im-
provements in FFRCT technology (updated proprietary
software with quantitative image quality analysis, improved
image segmentation, reﬁned physiological models, and
increased automation), as well as emphasis on the coronary
CTA image acquisition protocol to reﬂect current guidelines
(18). The study protocol was approved at each of the 10
participating centers (Online Appendix) by the local insti-
tutional review board. All study subjects provided written
informed consent.
Study population. Coronary CTA performed <60 days
before scheduled nonemergent ICA was required for in-
clusion. As pre-speciﬁed (17), the ﬁrst 100 patients included
in the study had no requirements with regard to coronary
stenosis severity. Beginning with patient 101, at least 1
stenosis with luminal diameter reduction between 30% and
90% in a vessel segment 2 mm in diameter according to
coronary CTA was required. Exclusion criteria included
previous coronary intervention or coronary bypass surgery;
contraindications to beta-blocking agents, nitroglycerin, or
adenosine; suspected acute coronary syndrome; previous
myocardial infarction <30 days before coronary CTA or
between coronary CTA and ICA; and body mass index
>35 kg/m2.Biotronik, and Medtronic. Dr. Achenbach has received research grants from Siemens,
Guerbet, and Abbott; and is a consultant for Siemens, Biotronik, and HeartFlow.
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1147Coronary CTA acquisition and analysis. Coronary CTA
was performed by using single- or dual-source computed
tomography (CT) scanners with a minimum of 64 detector
rows (temporal resolution 75 to 175 ms). Both prospective
triggering and retrospective gating were used for scan ac-
quisitions. Filtered back-projection was used for image
reconstruction to ensure the broadest applicability of our
ﬁndings given that this is the current clinical standard of
care. Laboratories followed quality standards as deﬁned in
guidelines (18). Oral and/or intravenous beta-blockers were
administered targeting a heart rate of <60 beats/min, and
sublingual nitrates were administered to ensure coronary
vasodilation. Data acquisition was performed with 100-kV
tube voltage in patients weighing 70 kg and 120 kV in
subjects weighing >70 kg. Coronary CTA images were
transmitted to a central FFRCT core laboratory (HeartFlow,
Inc., Redwood City, California), where image artifacts (e.g.,
motion, noise, contrast, blooming) were independently
evaluated by using a predeﬁned scoring system for selection
of cases appropriate for FFRCT analysis (17,19). Experi-
enced local investigators evaluated luminal diameter stenosis
in each coronary artery segment 2 mm in diameter by
using an 18-segment coronary model before ICA (18). The
strategy of stenosis quantiﬁcation was at the discretion of the
local investigator. Signiﬁcant obstruction was deﬁned as
stenosis >50% in a major epicardial coronary artery
segment 2 mm in diameter.
ICA and FFR measurement. ICA was performed ac-
cording to standard practice (20). Angiograms were trans-
ferred to the angiography/FFR core laboratory (Harrington
Heart and Vascular Institute, University Hospitals, Cleve-
land, Ohio) for quantitative angiography analysis by inde-
pendent, blinded readers. Per protocol, measurement of
FFR (PressureWire, St. Jude Medical, St. Paul, Minnesota)
was performed during ICA in at least 1 vessel segment with
diameter 2 mm and stenosis 30% (17). Consistent with
previous studies (1), segments showing angiographic total or
subtotal occlusion were assigned an FFR value of 0.50. The
angiography/FFR core laboratory evaluated the complete
FFR tracings for achievement of steady-state maximal
hyperemia, pressure drift, and other artifacts that could
compromise FFR interpretation.
FFRCT computation. Using the most recent generation of
FFRCT analysis software, analysis was performed in a blin-
ded fashion at HeartFlow (Fig. 1) (14,17). For each patient,
a quantitative 3-dimensional anatomic model of the aortic
root and epicardial coronary arteries was generated from
coronary CTA images. Coronary blood ﬂow and pressure
were computed under conditions simulating maximal hy-
peremia. The results provide FFRCT throughout the coro-
nary arterial tree. Occluded arteries were assigned FFRCT
values of 0.50 (1). The FFRCT analysis required 1 to 4 h per
examination depending on the CT image quality and
atherosclerotic disease burden.
Integration of coronary CTA and FFR data. The angio-
graphy/FFR core laboratory received a blank 3-dimensionalcomputer model of the coronary anatomy from the FFRCT
core laboratory; on this model, they indicated location(s)
corresponding to the FFR pressure sensor location(s) at the
time of FFR measurement(s). The blinded integration core
laboratory (HeartFlow) received the FFR measurement
location indication(s) and reported corresponding FFRCT
data. Integration of FFR and FFRCT data occurred only
after all FFRCT analyses for all patients were complete.
Endpoints and statistical analysis. The primary study
endpoint was per-patient diagnostic performance as assessed
by the area under the receiver-operating characteristic curve
(AUC) of FFRCT (0.80) versus coronary CTA (stenosis
>50%) for the diagnosis of hemodynamically signiﬁcant
stenosis (FFR 0.80) in patients with coronary CTA
stenosis of 30% to 90%. FFR 0.80 was the reference
standard. Secondary endpoints included assessment of
diagnostic accuracy, sensitivity, speciﬁcity, positive predictive
value (PPV), and negative predictive value (NPV) of FFRCT
and coronary CTA for all patients, patients with interme-
diate stenoses (30% to 70%), vessel-based analyses, and
comparison of accuracy measures of FFRCT, coronary CTA,
and ICA by using invasive FFR as the reference standard.
Furthermore, diagnostic performance was assessed on a per-
patient basis by using a stenosis threshold of 70% for cor-
onary CTA and ICA and in the setting of a high Agatston
score (threshold 400). Sample size calculations with as-
sumptions have been described previously (17). Pre-test
likelihood of CAD was determined by using the updated
Diamond-Forrester risk score algorithm (4,21). AUC
comparisons in patients with stenoses 30% to 90% were
performed on per-patient and per-vessel levels according to
the method described by DeLong et al. (22). Diagnostic
accuracy, sensitivity, speciﬁcity, PPV, and NPV were
calculated as simple proportions with 95% conﬁdence in-
tervals (CIs). Nonevaluable segments on coronary CTA in
vessels >2 mm were assumed not to be stenotic. A patient
was considered positive for the presence of ischemia if any
evaluable vessel 2 mm in diameter had an FFR
value 0.80. Similarly, a patient was considered negative if
no vessel 2 mm in diameter had an FFR value 0.80. The
same rules applied for the assessment of FFRCT. Patient-
level comparison of diagnostic performance characteristics
(accuracy, sensitivity, speciﬁcity, PPV, and NPV) was per-
formed by using the McNemar’s test for paired samples or
percentile bootstrap with 100,000 resamples as appropriate.
To account for potential correlation between multiple vessels
in the same subject, the generalized estimating equation
method with an exchangeable correlation structure was used
to compare paired samples at a per-vessel level. All analyses
were performed by using SAS version 9.3 (SAS Institute,
Inc., Cary, North Carolina).Results
Patient characteristics. Among 365 patients undergoing
study screening between September 2012 and August 2013,
Figure 1 Schematic Presentation of the FFRCT Analysis
(A)Routine coronary computed tomography angiography data are received. (B)A quantitative 3-dimensional anatomicmodel is generated. (C) A physiologicalmodel of the coronary
microcirculation is derived from patient-speciﬁc data with 3 main principles: 1) resting coronary ﬂow proportional to myocardial mass; 2) microvascular resistance inversely
proportional to vessel size; and 3)microvascular resistance reduced to simulatemaximal hyperemia. (D)Physical laws of ﬂuid dynamics are applied to compute coronary blood ﬂow.
(E) Fractional ﬂow reserve derived from standard acquired coronary computed tomography angiography datasets (FFRCT) is calculated for each point in the coronary tree.
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Figure 2 Study Enrollment
*Rejected cases often had multiple artifacts. Motion/misregistration (n ¼ 27), high image noise (n ¼ 21), excessive calcium blooming (n ¼ 19), and low contrast to noise ratio
(n ¼ 19). yPrior coronary stent (n ¼ 1), severe pulmonary disease (n ¼ 1), progressive disease (n ¼ 1), elevated creatinine level (n ¼ 1), withdrawal of patient consent (n ¼ 7),
invasive coronary angiography >60 days after the time of coronary computed tomography angiography (CTA) (n ¼ 5), no coronary artery stenosis 30% to 90% according to site
readings (n ¼ 5). Adenosine not administered for fractional ﬂow reserve (FFR) (n ¼ 1), and unspeciﬁed (n ¼ 1). BMI ¼ body mass index; FFRCT ¼ fractional ﬂow reserve derived
from coronary computed tomography angiography datasets; ICA ¼ invasive coronary angiography; NXT ¼ Analysis of Coronary Blood Flow Using CT Angiography: Next Steps.
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1149a total of 8 patients were excluded immediately after coro-
nary CTA, and 47 (13%) did not pass the CT image quality
acceptance criteria (Fig. 2). After coronary CTA acceptance,
56 patients were not eligible for inclusion; Figure 2 provides
the reasons for their exclusion. Thus, 254 patients were
available for intention-to-diagnose analyses. Three subjects
did have a coronary stenosis between 30% and 90%. Hence,
251 subjects formed the basis for the primary endpoint
analysis. Comparison of FFR and FFRCT was performed in
484 vessels. FFR was directly measured in 468 vessels, and
an FFR value of 0.50 was assigned to 16 occluded vessels
(3%). In 22 (4.5%) vessels, a nondiagnostic segment on
coronary CTA was found proximal to the segment in which
the pressure wire was placed. Baseline characteristics of thestudy cohort are listed in Table 1, and characteristics related
to coronary CTA acquisition are provided in Table 2. The
mean Agatston score (measured in 214 patients) was 302.
The mean interval between coronary CTA and ICA was 18
days (range 1 to 55 days). Serious adverse events included 1
patient with coronary dissection during invasive FFR mea-
surement requiring percutaneous coronary intervention and
2 patients with transient cerebral ischemic attacks after ICA
and invasive FFR measurement. The per-patient and per-
vessel characteristics of coronary CTA, ICA, FFRCT, and
FFR are presented in Table 3.
Diagnostic performance of FFRCT, coronary CTA, and
ICA for diagnosis of ischemia. Per-patient and per-vessel
AUC for FFRCT were 0.90 (95% CI: 0.87 to 0.94) and 0.93
Table 1 Baseline Characteristics
Age, yrs
Mean  SD 64  10
Range 32–84
Male 162 (64)
Race
White 163 (64)
Asian 86 (34)
Diabetes 58 (23)
Hypertension 174 (69)
Hyperlipidemia 200 (79)
Current smoker 46 (18)
Previous myocardial infarction 5 (2)
Symptoms*
Typical angina 103 (52)
Atypical angina 74 (37)
Nonanginal chest pain 9 (5)
Dyspnea 12 (6)
Angina within the past month 198 (78)
Updated Diamond-Forrester risk score, % 57.8
Intermediate (20%–80%) pre-test risk 220 (87)
Body mass index, kg/m2 26  3
Creatinine, mg/dl 0.9  0.2
Left ventricular ejection fraction, % 62  7
Values are mean  SD, range, n (%), or %. N ¼ 254. *Data available in 198 patients.
Table 3
Patient and Vessel Characteristics According to
Coronary CTA, ICA, FFRCT, and FFR
Patients with coronary CTA maximum stenosis >50% 220 (87)
Patients with coronary CTA maximum stenosis >70% 84 (33)
Patients with intermediate-range stenoses (30%–70%) 235 (93)
Patients with FFRCT 0.80 106 (42)
Vessels with FFRCT 0.80 135 (28)
Agatston score* 302  468 (0–3,599)
Patients with Agatston score >400* 55 (26)
Patients with ICA maximum stenosis >50% 81 (32)
Patients with ICA maximum stenosis >70% 28 (11)
Patients with FFR 0.80 80 (32)
Vessels with FFR 0.80 100 (21)
Patients with FFR 0.80 in >1 vessel 15 (6)
Values are n (%) or mean  SD (range). N ¼ 254 patients and 484 for vessels. *Agatston score was
measured in 214 patients.
FFR ¼ fractional ﬂow reserve; FFRCT ¼ fractional ﬂow reserve derived from standard acquired
coronary computed tomography angiography datasets; ICA ¼ invasive coronary angiography; other
abbreviation as in Table 2.
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1150(0.91 to 0.95), respectively. Diagnostic accuracy, sensitivity,
speciﬁcity, PPV, and NPV for FFRCT on a per-patient basis
were 81%, 86%, 79%, 65%, and 93%, respectively (Table 4).
On a per-vessel basis, the values were 86%, 84%, 86%, 61%,
and 95%. In analyses restricted to patients with intermediate
stenoses ranging from 30% to 70% (n ¼ 235), these values
were 80%, 85%, 79%, 63%, and 92% (Table 5). There was
good direct correlation of per-vessel FFRCT to FFR (Pear-
son’s correlation coefﬁcient 0.82; p < 0.001), with a slight
underestimation of FFRCT compared with FFR (Fig. 3).
Figure 4 displays representative cases of patients with cor-
onary obstructions without ischemia or with ischemia.
Measures of diagnostic performance for coronary CTA and
ICA are shown in Table 4. Raising the per-patient diameter
stenosis threshold for anatomic test positivity to 70%
resulted in lower sensitivity and higher speciﬁcity: 70% (95%
CI: 60% to 79%) and 84% (95% CI: 79% to 90%) forTable 2 Coronary CTA Acquisition Characteristics
Heart rate, beats/min
Mean  SD 63  10
Range 37–110
Pre-scan administration of nitrates 253 (99.6)
Pre-scan administration of beta-blockers 198 (78)
Prospective acquisition 138 (54)
Retrospective acquisition 116 (46)
Effective CT radiation dose, mSv
Prospective acquisition 3.0  2.2
Retrospective acquisition 14.3  7.0
Values are mean  SD, range, or n (%). N ¼ 254.
CT ¼ computed tomography; CTA ¼ computed tomography angiography.coronary CTA. For ICA, the respective values were 35%
(95% CI: 25% to 46%) and 100% (95% CI cannot be
calculated). In patients with an Agatston score >400, ac-
curacy, sensitivity, and speciﬁcity of FFRCT were 75%
(95% CI: 62% to 84%), 88% (95% CI: 64% to 97%), and
69% (95% CI: 54% to 81%) versus 44% (95% CI: 31% to
56%), 94% (95% CI: 79% to 100%), and 23% (95% CI: 11%
to 37%) for coronary CTA, respectively.
Diagnostic performance of FFRCT versus coronary CTA
for diagnosis of ischemia. The AUC of FFRCT was higher
than for coronary CTA interpretation on both a per-patient
and a per-vessel level (Fig. 5). Per-patient and per-vessel
diagnostic accuracy, speciﬁcity, and PPV for FFRCT were
higher than for coronary CTA (Table 4). These ﬁndings
were consistent also in patients with intermediate coronary
stenoses (Table 5). FFRCT correctly reclassiﬁed 68% of
patients with coronary CTA false-positive ﬁndings and 67%
of those with coronary CTA false-positive vessels as true
negative ﬁndings (Fig. 6).Discussion
This large study convincingly found that noninvasive deter-
mination of FFR is possible on the basis of standard coronary
CTA datasets acquired under resting conditions with no
additional radiation, contrast, or medication. In patients sus-
pected of having CAD, FFRCT exhibited a very high diag-
nostic performance compared with invasively measured
FFR. Particularly noteworthy was the high speciﬁcity of
FFRCT, which was markedly better than in a previous evalu-
ation of FFRCT (16). Moreover, compared with coronary
CTA, FFRCT led to a marked reduction in false-positive
results. Of note is the fact that patients with stenoses in the
intermediate range (30% to 70%) comprised >90% of the
overall study population. In clinical practice, such patients
present a particular challenge because the relationship bet-
ween angiographic stenosis severity and ischemia is poor (1,13).
Ta
bl
e
4
P
er
-P
at
ie
nt
an
d
P
er
-V
es
se
l
D
ia
g
no
st
ic
P
er
fo
rm
an
ce
of
FF
R
C
T
,
C
or
on
ar
y
C
TA
,
an
d
IC
A
P
er
-P
at
ie
nt
P
er
-V
es
se
l
C
or
on
ar
y
C
TA
S
te
no
si
s
>
5
0
%
p
V
al
ue
FF
R
C
T
0
.8
0
p
V
al
ue
IC
A
S
te
no
si
s
>
5
0
%
C
or
on
ar
y
C
TA
S
te
no
si
s
>
5
0
%
p
V
al
ue
FF
R
C
T
0
.8
0
p
V
al
ue
IC
A
S
te
no
si
s
>
5
0
%
A
cc
ur
ac
y
5
3
(4
7
–
5
7
)
<
0
.0
0
1
8
1
(7
6
–
8
5
)
0
.0
9
7
7
(7
1
–
8
2
)
6
5
(6
1
–
6
9
)
<
0
.0
0
1
8
6
(8
3
–
8
9
)
0
.0
3
2
8
2
(7
9
–
8
6
)
Se
ns
iti
vi
ty
9
4
(8
6
–
9
7
)
0
.0
5
8
8
6
(7
7
–
9
2
)
<
0
.0
0
1
6
4
(5
3
–
7
4
)
8
3
(7
4
–
8
9
)
0
.9
1
8
4
(7
5
–
8
9
)
<
0
.0
0
1
5
5
(4
5
–
6
5
)
Sp
ec
iﬁ
ci
ty
3
4
(2
7
–
4
1
)
<
0
.0
0
1
7
9
(7
2
–
8
4
)
0
.2
9
8
3
(7
7
–
8
8
)
6
0
(5
6
–
6
5
)
<
0
.0
0
1
8
6
(8
2
–
8
9
)
0
.1
6
9
0
(8
6
–
9
3
)
P
P
V
4
0
(3
3
–
4
7
)
<
0
.0
0
1
6
5
(5
6
–
7
4
)
0
.3
4
6
3
(5
2
–
7
3
)
3
3
(2
7
–
3
9
)
<
0
.0
0
1
6
1
(5
3
–
6
9
)
0
.1
8
5
8
(4
8
–
6
8
)
N
P
V
9
2
(8
3
–
9
7
)
0
.4
6
9
3
(8
7
–
9
6
)
<
0
.0
0
1
8
3
(7
7
–
8
9
)
9
2
(8
8
–
9
5
)
0
.0
6
8
9
5
(9
3
–
9
7
)
<
0
.0
0
1
8
8
(8
5
–
9
2
)
Va
lu
es
ar
e
pr
op
or
tio
n,
%
(9
5
%
C
I).
FF
R
0
.8
0
w
as
di
ag
no
st
ic
of
le
si
on
-s
pe
ci
ﬁ
c
is
ch
em
ia
.N
¼
2
5
4
su
bj
ec
ts
an
d
4
8
4
fo
r
ve
ss
el
s.
N
P
V
¼
ne
ga
tiv
e
pr
ed
ic
tiv
e
va
lu
e;
P
P
V
¼
po
si
tiv
e
pr
ed
ic
tiv
e
va
lu
e;
ot
he
r
ab
br
ev
ia
tio
ns
as
in
Ta
bl
es
2
an
d
3
.
JACC Vol. 63, No. 12, 2014 Nørgaard et al.
April 1, 2014:1145–55 FFR Derived From Standard Acquired Coronary CTA
1151The results of our study expand on ﬁndings and clinical
implications from previous studies of FFRCT (15,16). The
pilot DISCOVER-FLOW (Diagnosis of Ischemia-Causing
Stenoses Obtained Via Noninvasive Fractional Flow
Reserve) trial enrolled 103 subjects, validated against inva-
sive FFR, and reported a per-vessel sensitivity of 88% and a
speciﬁcity of 82% (15). The more recent DeFACTO
(Determination of Fractional Flow Reserve by Anatomic
Computed Tomographic Angiography) trial enrolled 252
patients, validated against FFR, and demonstrated a per-
patient sensitivity of 90% but a speciﬁcity of only 54%,
which did not meet the pre-speciﬁed primary endpoint of a
lower 95% CI border for diagnostic accuracy of >70% (16).
The improved diagnostic performance of FFRCT in the
present study, in particular with regard to speciﬁcity,
importantly reﬂects substantial reﬁnements in FFRCT
technology and physiological modeling (14,17), as well as
an increased focus on CT image quality (17) and adherence
to ofﬁcial recommendations regarding coronary CTA
acquisition (18). Reﬁnements in technology evaluated in
this study included improved automated image processing
methods to more accurately identify the luminal boundary
and improved physiological models to reduce the bias
observed in previous studies (15,16). In particular, im-
provements in physiological models of microcirculatory
resistance were implemented that demonstrated substantial
improvement in diagnostic performance when evaluated
retrospectively by using data from the DISCOVER-FLOW
and DeFACTO studies. The importance of CT image
quality and patient preparation in coronary CTA has been
well established (18). The diagnostic performance of both
coronary CTA and FFRCT have been shown to improve
with adherence to established best practices for image
acquisition, particularly by heart rate control and use of pre-
scan nitroglycerin (23). In the DISCOVER-FLOW and
DeFACTO trials, adherence to coronary CTA acquisition
guidelines was neither required nor controlled. In contrast,
in the present study, strict adherence to these guidelines was
mandatory. Accordingly, >99% of the patients in this study
received sublingual nitrates before coronary CTA compared
with only 75% of patients in the DeFACTO trial (16). In
addition, the present study used local site reading of coro-
nary CTA stenosis degree to provide a real-world scenario
and wider generalizability of the ﬁndings (24). Moreover,
as indicated by differences in the proportion of FFR
measurements 0.80 (21% of vessels in this study compared
with 37% in the DeFACTO study), pre-test likelihood of
CAD may have been different between the 2 studies.
Notably, the pre-test probability of signiﬁcant CAD in this
study was intermediate (4,21) and thus reﬂective of the type
of patients in whom noninvasive imaging is best used (4).
Established noninvasive functional diagnostic tests, such
as single photon emission computed tomography, cMR,
or stress echocardiography, do not directly visualize the
coronary arteries or assess the functional signiﬁcance of
individual coronary lesions; however, they do provide
Table 5
Per-Patient Diagnostic Performance of FFRCT in
Patients With Intermediate Stenosis Severity
(30% to 70%) According to Coronary CTA
FFRCT 0.80 Coronary CTA Stenosis >50% p Value
Accuracy 80 (75–85) 51 (44–57) <0.0001
Sensitivity 85 (74–91) 93 (85–97) 0.058
Speciﬁcity 79 (72–84) 32 (26–40) <0.0001
PPV 63 (53–72) 37 (31–44) <0.0001
NPV 92 (87–96) 91 (81–96) 0.42
Values are proportion in % (95% conﬁdence interval). FFR 0.80 was diagnostic of ischemia.
N ¼ 235.
Abbreviations as in Tables 2 through 4.
Figure 3
Bland-Altman Plot of FFR and FFRCT on a
Per-Vessel Basis
Abbreviations as in Figure 2.
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1152meaningful information on prognosis and thus are re-
commended in guidelines for the diagnostic evaluation of
symptomatic patients (4). The ability of these tests to
correctly identify ischemia-producing stenoses by using FFR
as the reference standard has been evaluated in several 1- and
2-center studies (25–27). In 1 study, cMR was compared
with FFR 0.80 in 103 patients with suspected angina, with
high reported per-vessel diagnostic performance (i.e., sensi-
tivity of 82% and speciﬁcity of 98%) (25). However, FFR was
directly measured in only 207 vessels (or 69% of the 300
coronary segments included in this analysis). Another study
compared cMR with FFR 0.80 in 67 patients with mul-
tivessel disease and reported a per-vessel sensitivity of 61%
and a speciﬁcity of 69%, with direct measurement of FFR
in 154 vessels (77%) supplying 201 vascular territories
included in the analysis (26). A third study investigating
the diagnostic performance of dobutamine stress echocardi-
ography in 70 patients measured FFR in all 70 vessels
included in the analysis and reported a sensitivity of 48%
and a speciﬁcity of 73% (27). Inclusion of a sizable number
of vessels with assigned rather than measured FFR values
may introduce error because vessels with normal or minimal
disease according to CT or angiography may have measured
FFR 0.80 (2,13), and severely stenosed vessels by angi-
ography may have measured FFR >0.80 (1,13). In the
present, large, multicenter study, FFR values were directly
measured in 97% of the 484 vessels included in the analysis,
and per-vessel sensitivity and speciﬁcity for FFRCT were
84% and 86%, respectively.
In an era of rising healthcare costs, great attention is placed
on cost-effectiveness of procedures. Current clinical algo-
rithms for therapeutic decision making in stable CAD often
require 2 separate tests for assessment of coronary anatomy
and ischemia (4,5). Despite extensive use of noninvasive
testing, ICA continues to play a major role in diagnostic
pathways (4–6). As a result of inadequate diagnostic
discrimination with the use of noninvasive tests, up to 60% of
subjects suspected of having CAD and referred for ICA do
not have obstructive vessel narrowing (6), and the proportion
without functionally signiﬁcant myocardial ischemia would
be expected to be even higher. A single noninvasive test with
high diagnostic performance for both anatomy and lesion-
speciﬁc ischemia would provide a major advantage inassessment of CAD. Our data ﬁrmly establish that myocar-
dial ischemia is unlikely in patients tested negative by using
FFRCT (NPV of 93%). Moreover, FFRCT revealed sub-
stantially improved speciﬁcity compared with coronary CTA.
The present ﬁndings supporting the potential role of coro-
nary CTA with FFRCT as a reliable gatekeeper to ICA and
revascularization, together with the worldwide, ever-
expanding access to coronary CTA (12), may have major
health and economic implications. Indeed, simulation ana-
lyses based on historical data indicate that use of FFRCT to
guide selection of ICA and revascularization may reduce
costs and improve clinical outcomes in patients suspected of
having CAD (28). The ongoing multicenter PLATFORM
(Prospective Longitudinal Trial of FFRCT: Outcome and
Resource Impacts; NCT01943903) trial compares the
effect of FFRCT-guided testing versus standard diagnostic
evaluation on clinical outcomes, resource utilization, costs,
and quality of life in patients suspected of CAD.
Study limitations. In the present study, 13% of patients
were judged to have nonevaluable coronary CTA images on
the basis of a pre-deﬁned image quality score (17,19). This
proportion may diminish with further improvement of
CT acquisition techniques and reﬁnement of the FFRCT
technology. The number of patients eligible for study in-
clusion (having ICA performed after coronary CTA) but
not recruited was not recorded; therefore, site-level selec-
tion bias on the basis of coronary CTA ﬁndings cannot be
excluded. However, the pre-test risk of CAD, as well as the
spectrum and prevalence of disease (e.g., with regard to
Agatston scores, as well as coronary CTA and FFR positive
results), in this trial support the generalizability of the
ﬁndings. Patients with acute coronary syndromes and pre-
vious coronary intervention or bypass surgery were excluded
from the present study. Thus, generalizability of FFRCT to
Figure 4 Representative Examples of Subjects From the NXT Study
(A) Multiplanar reformat of (a) coronary computed tomography (CT) angiogram, (b) invasive coronary angiogram, (c) invasive FFR measurement, and (d) FFRCT of the left
coronary artery system. Coronary CT angiogram demonstrates obstructive stenosis of the mid-portion of the left anterior descending artery (red arrow) and an FFRCT value of
0.93, indicating absence of lesion-speciﬁc ischemia. Invasive coronary angiogram demonstrates obstructive stenosis of the mid-portion of the left anterior descending artery
(red arrow) and a measured FFR value of 0.94, indicating no ischemia. (B) Multiplanar reformat of (a, d) coronary CT angiograms, (right side of d) straightened curved planar
reformat of the coronary CT angiogram, (b, e) invasive coronary angiograms, (c, f) invasive FFR measurements, and (g) FFRCT of the right coronary artery and left anterior
descending artery, respectively. The coronary CT angiogram demonstrates obstructive stenosis of the distal portion of the right coronary artery and the mid-portion of the left
anterior descending artery (red arrows) and FFRCT values of 0.56 and 0.75 indicating ischemia. Invasive coronary angiogram demonstrates obstructive stenoses of the right
coronary and left anterior descending arteries (red arrows) and measured FFR values, indicating ischemia in both vessel territories. Abbreviations as in Figures 2 and 3.
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Figure 5 AUC of FFRCT Versus Coronary CTA for Demonstration of Ischemia (FFR 0.80) on a Per-Patient and Per-Vessel Basis
(A) Per-patient; (B) per-vessel. In the per-patient analysis, a FFRCT 0.80 was diagnostic of ischemia, and stenosis >50% at coronary CTA was anatomically obstructive. N ¼
251 for subjects and 484 for vessels. AUC ¼ area under the receiver-operating characteristic curve; other abbreviations as in Figures 2 and 3.
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unknown.
Conclusions
This study found that FFRCT has high diagnostic per-
formance compared with invasively measured FFR,A
Figure 6 Agreement for Detection of Ischemia (FFR 0.80) Betwee
(A) Coronary CTA; (B) FFRCT. N ¼ 254 for subjects and 484 for vessels. Abbreviations aidentifying patients with hemodynamically relevant
obstructions with high sensitivity and speciﬁcity.
Compared with anatomic interpretation by using coro-
nary CTA, FFRCT led to a marked increase in diagnostic
speciﬁcity. The addition of FFRCT to coronary CTA may
allow for a comprehensive anatomic and functional
assessment of CAD in a manner potentially promotingB
n Coronary CTA and FFRCT on a Per-Patient and Per-Vessel Basis
s in Figures 2 and 3.
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1155beneﬁcial clinical and cost outcomes, which remain to be
deﬁnitively proven in appropriately designed prospective
trials.
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For the participating study centers, please see the online version of this
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